Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
sertraline | ANDA | 2025-02-26 |
sertraline hcl | ANDA | 2024-05-16 |
sertraline hydrochloride | ANDA | 2025-04-07 |
sertraline hydrochloride tablets | ANDA | 2009-08-20 |
zoloft | New Drug Application | 2023-08-15 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Sertraline |
INN | sertraline |
Description | Sertraline is a member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder. It has a role as an antidepressant and a serotonin uptake inhibitor. It is a member of tetralins, a secondary amino compound and a dichlorobenzene. It is a conjugate base of a sertraline(1+). It derives from a hydride of a tetralin. |
Classification | Small molecule |
Drug class | selective serotonin reuptake inhibitors (SSRI) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 |
PDB | — |
CAS-ID | 79617-96-2 |
RxCUI | — |
ChEMBL ID | CHEMBL809 |
ChEBI ID | 9123 |
PubChem CID | 68617 |
DrugBank | DB01104 |
UNII ID | QUC7NX6WMB (ChemIDplus, GSRS) |